Drug Patents owned by Ferring

1. Drug name - FIRMAGON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9579359 FERRING Method of treating prostate cancer with GnRH antagonist Feb, 2029

(6 years from now)

US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist Feb, 2029

(6 years from now)

US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist Feb, 2029

(6 years from now)

US9415085 FERRING Method of treating prostate cancer with GnRH antagonist Apr, 2032

(9 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist Apr, 2032

(9 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 80MG BASE/VIAL POWDER;SUBCUTANEOUS Prescription
EQ 120MG BASE/VIAL POWDER;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.